November 14, 2025

The Risk Factor Going Unscreened

Adverse childhood experiences drive elevated all-cause mortality across medical conditions, with emergency department patients also showing nearly double the death rates.

Conexiant

November 13, 2025

TAVR Matched Surgery at 7 Years

Outcomes were compared between transcatheter and surgical valve procedures.

Conexiant

November 12, 2025

This Week’s Biopharma News: Clinical Hold for Heart Disease Gene Therapy

Our latest news roundup reports on Novartis’ new radioligand facility in California, new tech for boosting AAV yields, and MeiraGTx’s deal with Eli Lilly

The Medicine Maker

November 12, 2025

Radiation Training Levels May Influence Safety Culture

Researchers examine how radiation knowledge shapes health care safety attitudes.

Conexiant

November 12, 2025

Dual Therapy for Coronary Disease: How Safe Is It? 

Adding aspirin to long-term oral anticoagulation in patients with chronic coronary syndrome increased mortality and major bleeding without improving cardiovascular outcomes.

Conexiant

November 11, 2025

Model for Predicting Risk of Heart Failure or Cardiomyopathy After Breast Cancer Treatment

In a study reported in JAMA Oncology, Barac et al developed a risk prediction model for heart failure or cardiomyopathy after breast cancer treatment.

The ASCO Post

November 11, 2025

Long-Term Use of Sleep Supplement Melatonin Linked to Potential Heart Risks

A new study suggests that long-term use of melatonin may carry significant health risks, particularly for the heart.

Baptist Health South Florida

November 11, 2025

Gene Editing Lowers Cholesterol in Early Trial

At the highest tested dose, a single IV CRISPR therapy reduced LDL cholesterol by ~49% and triglycerides by ~55% at 60 days in patients with treatment-resistant dyslipidemia.

Conexiant

November 11, 2025

Testing Metformin’s Reach in PAD

Double-blind trial of 202 patients shows no improvement in 6-minute walk distance at 6 months compared with placebo.

Conexiant